The objective of the study presented was to show that Image Analysis (IA) approaches can deliver a more quantitative IHC score by objectively distinguishing tumor component and cellular compartments, detecting minor differences in staining intensity, and by preforming its function across the whole tumor section. However, most current IA approaches are designed only to report an average of staining across a small analyzed region, without reporting the cell-by-cell or tissue compartment measurements required to identify discrete endpoints.
Using the whole tissue slide, Flagship Biosciences is able to provide these as discrete evaluations or multiplex these evaluations for an integrative answer which can be derived from a typical clinical biopsy. Incorporation of these novel tools will enable ADC developers to create efficacy and patient stratification paradigms which incorporate the critical biological endpoints unique to ADCs.
